RGMP OTC
Regnum Corp.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: +0.0%
3Y: -99.9%
5Y: -99.8%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.0001-0.0001
Volume600
Avg Volume562
Beta-0.80
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEORobert J. Stubblefield
Employees1
SectorCommunication Services
IndustryEntertainment
IPO Date2019-05-29
Websiteregnumcorp.com
600 Third Avenue
New York City, NY 10016
US
New York City, NY 10016
US
877 313 2232
About Regnum Corp.
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody CÂC chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company was incorporated in 2016 and is based in New York, New York.
Latest News
No recent news
Recent Insider Trades
No insider trades found